Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01122888 : Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

- Histologically confirmed solid tumor or malignant glioblastoma multiforme meeting ? 1
of the following criteria:

- Disease refractory to standard therapy

- No standard therapy exists

- Sunitinib malate monotherapy would be appropriate management

- Measurable disease is not required

- Previously treated brain metastases or primary brain neoplasms allowed provided
patient is not receiving concurrent corticosteroids

- Karnofsky performance status 70-100%

- ANC ? 1,500/?L

- WBC ? 3,000/?L

- Platelet count ? 100,000/?L

- Hemoglobin ? 9 g/dL

- Total bilirubin normal (unless due to documented Gilbert syndrome)

- AST and ALT < 2.5 times upper limit of normal (ULN) (< 5 times ULN in the presence of
liver metastases)

- Creatinine normal OR creatinine clearance ? 60 mL/min

- Serum calcium ? 12.0 mg/dL

- QTc < 500 msec

- Patients with any of the following are allowed provided they have NYHA class I-II
cardiac function and undergo a baseline ECHO/MUGA:

- History of class II heart failure and asymptomatic on treatment

- Prior anthracycline exposure

- Previously treated with central thoracic radiotherapy that included the heart in
the radiotherapy port

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective barrier contraception

- No history of allergic reactions attributed to compounds of similar chemical or
biologic composition to sunitinib malate

- No concurrent uncontrolled illness including, but not limited to, any of the

- Ongoing or active infection

- Symptomatic congestive heart failure

- Unstable angina pectoris

- Cardiac arrhythmia

- Psychiatric illness and/or social situation that would limit compliance with
study requirements

- No pre-existing thyroid abnormality for which thyroid function cannot be maintained
in the normal range with medication

- No documented thrombosis (pulmonary embolism or deep vein thrombosis) within the past
6 months

- No known coagulopathy or thrombophilia

- No provengastric or duodenal ulcer or clinically significant gastrointestinal (GI)
blood loss within the past 6 weeks

- No history of CNS hemorrhage

- No life-threatening bleeding diathesis within the past 6 months

- No history of serious ventricular arrhythmia (i.e., ventricular fibrillation or
ventricular tachycardia ? 3 beats in a row) or other significant ECG abnormalities

- No poorly controlled hypertension (i.e., systolic BP ? 150mm Hg or diastolic BP ? 100
mm Hg)

- No condition that would impair the ability to swallow and retain sunitinib malate
tablets, including any of the following:

- GI tract disease resulting in an inability to take oral medications or a
requirement for IV alimentation

- Prior surgical procedures affecting absorption

- Active peptic ulcer disease

- No gastrostomy, jejunostomy, or other forms of enteral tube feeding modalities

- None of the following conditions:

- Serious or non-healing wound or ulcer

- Abdominal fistula, GI perforation, or intra-abdominal abscess within the past 28

- Cerebrovascular accident or transient ischemic attackwithin the past 12 months

- Myocardial infarction, cardiac arrhythmia, stable/unstable angina, symptomatic
congestive heart failure, or coronary/peripheral artery bypass graft or stenting
within the past 12 months

- NYHA class III or IV heart failure

- Radiographically or physiologically diagnosed usual interstitial pneumonitis
(UIP) or non-specific interstitial pneumonitis (NSIP)

- No bone fracture within the past 12 months

- No other concurrent anticancer agents or therapies

- More than 4 weeks since prior radiotherapy or systemic antineoplastic therapy (6
weeks for nitrosoureas, mitomycin C, or bevacizumab) and recovered

- More than 2 weeks since prior hormone replacement therapy or hormonal contraceptives

- More than 1 month since prior surgery

- At least 7 days since prior and no concurrent CYP3A4 inhibitors

- At least 12 days since prior and no concurrent CYP3A4 inducers

- Prior luteinizing hormone-releasing hormone agonists for hormone-refractory prostate
cancer allowed

- Prior antiangiogenic agents (e.g., sorafenib, pazopanib, AZD2171, PTK787, or VEGF
Trap) allowed provided there is no disease progression

- No prior cilengitide or sunitinib malate

- No prior bevacizumab

- No other concurrent investigational agents

- No concurrent combination antiretroviral therapy for HIV-positive patients

- No concurrent agents with proarrhythmic potential (e.g., terfenadine, quinidine,
procainamide, disopyramide, sotalol, probucol, bepridil, haloperidol, risperidone,
indapamide, or flecainide)

- No concurrent palliative radiotherapy

- No other concurrent chemotherapy or biologic agents

- No concurrent medications that may cause QTc prolongation

- No concurrent therapeutic doses of coumarin-derivative anticoagulants (e.g.,

- Up to 2 mg of daily warfarin for the prophylaxis of thrombosis allowed

- Low-molecular weight heparin allowed provided PT/INR ? 1.5

- No concurrent grapefruit juice
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557